Jiawei Maxingshigan Powder Veterinary Grade API is a multi-component botanical material in which ephedrine alkaloids, amygdalin-derived benzaldehyde, calcium sulfate dihydrate, and glycyrrhizinic acid coexist in a non-stoichiometric but batch-certified ratio. Direct compression blends for oral tablets are constrained by the hygroscopic behaviour of the licorice fraction and the brittle fracture pattern of gypsum-containing particles. If direct compression blend moisture exceeds 6.0% LOD, powder bridging in the feed frame is observed, and tablet ejection force frequently rises above 1200 N. The API is therefore pre-dried in a vacuum tray dryer at 45°C and −0.08 MPa to a final loss on drying of 4.5–5.5%. Particle size is controlled after drying by passage through a 60-mesh sieve with a vibratory screener; retention above 250 µm is milled in a conical mill fitted with a 0.75 mm rasping screen at 2500 rpm. Final blend bulk density is 0.45–0.55 g/cm³, tapped density is 0.60–0.70 g/cm³, and the Hausner ratio is kept between 1.25 and 1.35. A representative batch formula contains API 30.0% w/w, microcrystalline cellulose 28.5% w/w, anhydrous dibasic calcium phosphate 35.0% w/w, crospovidone 4.0% w/w, colloidal silicon dioxide 2.0% w/w, and magnesium stearate 0.5% w/w. The ingredients except magnesium stearate are blended in a 600 L bin blender at 15 rpm for 20 minutes. Magnesium stearate is added last and blended for 3 minutes; excessive lubrication beyond 5 minutes decreases tablet hardness by 15–20% without improving ejection. Tablets are compressed on a 45-station rotary tablet press using 10 mm round punches, pre-compression force 6 kN, main compression force 18–24 kN, and turret speed 35–45 rpm. Terminal tablet hardness is 60–80 N, friability is ≤0.8% after 100 revolutions per USP <1216>, and disintegration in water at 37°C is ≤30 minutes per USP <701>. Content uniformity is tested per USP <905>; the acceptance value must not exceed 15.0.

What Filtration Train Is Required When Insoluble Calcium Sulfate Load Exceeds 10 mg/L in Parenteral Solution?

Injectable solution preparation from Jiawei Maxingshigan Powder Veterinary Grade API requires a clarified aqueous extract because the raw powder contains calcium sulfate dihydrate and lignocellulosic fragments that cannot be rendered soluble by pH adjustment. The water-soluble fraction is dissolved in Water for Injection at 20 mg/mL and adjusted to pH 5.5–6.5 with 0.1 N hydrochloric acid; ephedrine and pseudoephedrine remain protonated at this pH because their pKa values are near 9.6. Sodium chloride is added to achieve an osmolality of 280–320 mOsm/kg per USP <785>. After cooling to 20–25°C, the bulk solution is passed through a depth filter and a 0.45 µm PVDF membrane prefilter to reduce turbidity to below 5 NTU. Sterilizing filtration is performed with a 0.22 µm PVDF membrane; filter integrity is verified by bubble point per ASTM F838-20 before and after filling. Vials are depyrogenated at 250°C for 30 minutes and filled under ISO 14644-1:2015 Grade B conditions with Grade A laminar flow. Terminal steam sterilization at 121°C for 15 minutes may be applied only if stability data support it; published data for this specific botanical parenteral configuration is limited, so aseptic processing is the default route. The finished product is tested for sterility per USP <71>, bacterial endotoxins per USP <85>, and particulate matter per USP <788>.

During dosator-type capsule filling of low-bulk-density botanical extracts, plug retention force changes as moisture migrates from the capsule shell into the powder bed. Capsule formulations containing Jiawei Maxingshigan Powder Veterinary Grade API use a target fill weight of 400 mg in size 1 hard gelatin capsules. A representative dry blend is API 25.0% w/w, anhydrous lactose 40.0% w/w, microcrystalline cellulose 30.0% w/w, crospovidone 4.0% w/w, talc 0.5% w/w, and colloidal silicon dioxide 0.5% w/w. Anhydrous lactose is preferred over spray-dried lactose because the reducing sugar in spray-dried material accelerates Maillard browning with residual amino acid fractions from the botanical API when stored above 30°C. Ingredients are screened through a 40-mesh sieve and mixed in a 300 L V-blender at 18 rpm for 25 minutes. The dosator machine is set with a compression ratio of 1.2:1 and pin height 2 mm; fill weight variation is held to ±5% of target. Empty capsule shells are conditioned at 22–25°C and 45–50% RH for 24 hours before filling. Final capsule LOD is controlled to ≤7.0% to prevent shell brittleness and seam splitting. Content uniformity is tested per USP <905> with an acceptance value of ≤15.0; disintegration in water at 37°C is ≤30 minutes per USP <701>. Aluminum-PVC cold-form blister packaging with desiccant is specified as the terminal package because moisture ingress above 60% RH causes softening and cross-contamination of the botanical powder with plasticizer residues.

Premix Homogeneity Limits and Medicated Feed Carryover Control

Carrier selection for low-inclusion botanical premixes is constrained by particle shape, oil absorption, and electrostatic charge. A 50 g/kg concentrate is prepared by geometrically diluting Jiawei Maxingshigan Powder Veterinary Grade API into ground rice hulls 70% w/w, calcium carbonate 25% w/w, and soybean oil 2% w/w. The carrier is screened through a 20-mesh sieve before mixing. Mixing is performed in a 1000 kg ribbon blender at 12 rpm for 15 minutes; ten sampling points are drawn from the center and corners using a grain probe. Acceptance requires a coefficient of variation of active marker not more than 5.0%. The premix is transferred by low-pressure pneumatic conveying below 0.5 bar to prevent fines segregation; dense-phase conveying above 1.5 bar has been observed to strip the botanical fines from the rice hull carrier. Terminal 25 kg paper bags with polyethylene liners are used. When the premix is added to complete feed at 2 kg/ton, the final feed mix must be sampled at 12 points and achieve a CV of ≤7.5% before release. Facilities operating under 21 CFR Part 225 must validate flush cycles and use separate bins for medicated and non-medicated feed because cross-contact with ionophore-containing feeds may produce incompatible residues in mixed species operations.

When Wet Granulation Is Used for Oral Granule Reconstitution, Binder Viscosity Rather Than Wet Mass Torque Controls Yield

Wet granulation of Jiawei Maxingshigan Powder Veterinary Grade API for sachet delivery is controlled by binder solution rheology because the botanical matrix absorbs water unevenly. A 5% w/w povidone K30 solution is sprayed into a 600 L high-shear granulator charged with API 40.0% w/w, sorbitol 15.0% w/w, mannitol 20.0% w/w, pregelatinized starch 20.0% w/w, and croscarmellose sodium 5.0% w/w. The impeller is set to 150 rpm and the chopper to 1500 rpm; binder solution is sprayed at 0.8 kg/min over 8–10 minutes until the wet mass reaches 12–15 N·m torque. Overgranulation increases the fraction of granules larger than 1.0 mm and extends reconstitution time beyond 120 seconds. Povidone K90 is not substituted because its higher solution viscosity leads to surface crusting and non-uniform binder distribution. The wet mass is discharged through a 4.0 mm screen and dried in a fluid bed dryer with inlet air at 60°C until LOD is 2.5–3.5%. Dry granules are sieved through a 1.25 mm screen; fines below 150 µm are limited to ≤20% to preserve flow into stick-pack form-fill-seal equipment. A 5.0 g sachet is filled under 25–30% RH; each sachet contains a unit dose determined by ephedrine alkaloid assay. Content uniformity is tested per USP <905>; dissolution is assessed using USP <711> apparatus II at 50 rpm in 900 mL water at 37°C with sampling at 15, 30, and 45 minutes. Bottles or sachets are packed with molecular sieve desiccant because residual moisture above 4.0% promotes binder migration and speck formation.

Because reconstitution time of a multi-component powder is governed by particle size distribution rather than total active content, control begins with micronization of water-insoluble gypsum fractions. A dry oral suspension formulation contains API 15.0% w/w, xylitol 30.0% w/w, pregelatinized starch 30.0% w/w, citric acid 5.0% w/w, sodium bicarbonate 5.0% w/w, xanthan gum 0.3% w/w, colloidal silicon dioxide 1.0% w/w, and orange flavor 0.5% w/w. The powder is screened through a 0.180 mm sieve to achieve D90 ≤180 µm and D50 ≤90 µm. Mixing is performed in a 400 L V-blender at 20 rpm for 30 minutes; blend uniformity is tested by sampling 10 positions and assaying ephedrine alkaloid with a relative standard deviation of ≤5.0%. A 20 g unit dose is filled into laminated foil sachets at 22–25°C and 35–40% RH. Reconstitution in 100 mL water at 25–35°C with gentle stirring for 60 seconds yields a suspension with pH 5.0–6.0. Sedimentation volume after 24 hours is ≥0.80; redispersibility requires no more than 3 inversions. Microbiological quality is tested per USP <61> and USP <62>, with total aerobic microbial count ≤10³ CFU/g, total combined yeasts and molds ≤10² CFU/g, and absence of Escherichia coli in 1 g. The sachet material is aluminum-foil laminate to limit oxygen permeation below 0.1 cm³/m²/day because the licorice-derived glycyrrhizin fraction oxidizes under accelerated light and oxygen exposure.